Lawmakers question FTC's actions in Watson pharma investigation
Thursday, 29 July 2010
Ron Knox
Lawmakers this week questioned US Federal Trade Commission Chairman Jon Leibowitz over accusations that the commission committed misconduct in the course of a reverse payment settlement pharmaceutical investigation.
PREMIUM Subscription required to view this article
This content can only be accessed by PREMIUM GCR subscribers.
A premium subscription includes 10 issues of the journal, 2 signature surveys - The GCR100 and Rating Enforcement, 10 GCR special reports and full access to current and archived print & online content.
If you are a GCR subscriber, please login to access this content:
Comments
You must Subscribe or Log In to make comments.
Comment Terms & Conditions
Back to top